CN120550150A - 使用靶向放射治疗（trt）来驱动对免疫疗法的抗肿瘤免疫反应 - Google Patents

使用靶向放射治疗（trt）来驱动对免疫疗法的抗肿瘤免疫反应

Info

Publication number
CN120550150A
CN120550150A CN202510688757.2A CN202510688757A CN120550150A CN 120550150 A CN120550150 A CN 120550150A CN 202510688757 A CN202510688757 A CN 202510688757A CN 120550150 A CN120550150 A CN 120550150A
Authority
CN
China
Prior art keywords
tumor
antibodies
tumors
mice
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510688757.2A
Other languages
English (en)
Chinese (zh)
Inventor
J·魏歇特
P·松德尔
R·帕特尔
Z·莫里斯
P·卡尔森
R·赫南德茲
J·格鲁得辛斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/809,427 external-priority patent/US11633506B2/en
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of CN120550150A publication Critical patent/CN120550150A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0408—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N2005/1019—Sources therefor
    • A61N2005/1021—Radioactive fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202510688757.2A 2017-11-10 2018-11-09 使用靶向放射治疗（trt）来驱动对免疫疗法的抗肿瘤免疫反应 Pending CN120550150A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15/809,427 2017-11-10
US15/809,427 US11633506B2 (en) 2016-07-18 2017-11-10 Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
CN201880086000.4A CN111565762A (zh) 2017-11-10 2018-11-09 使用靶向放射治疗(trt)来驱动对免疫疗法的抗肿瘤免疫反应
PCT/US2018/059927 WO2019094657A1 (en) 2017-11-10 2018-11-09 Using targeted radiotherapy (trt) to drive anti-tumor immune response to immunotherapies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880086000.4A Division CN111565762A (zh) 2017-11-10 2018-11-09 使用靶向放射治疗(trt)来驱动对免疫疗法的抗肿瘤免疫反应

Publications (1)

Publication Number Publication Date
CN120550150A true CN120550150A (zh) 2025-08-29

Family

ID=64665595

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880086000.4A Pending CN111565762A (zh) 2017-11-10 2018-11-09 使用靶向放射治疗(trt)来驱动对免疫疗法的抗肿瘤免疫反应
CN202510688757.2A Pending CN120550150A (zh) 2017-11-10 2018-11-09 使用靶向放射治疗（trt）来驱动对免疫疗法的抗肿瘤免疫反应

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201880086000.4A Pending CN111565762A (zh) 2017-11-10 2018-11-09 使用靶向放射治疗(trt)来驱动对免疫疗法的抗肿瘤免疫反应

Country Status (7)

Country Link
EP (1) EP3706808A1 (enrdf_load_stackoverflow)
JP (2) JP2021502368A (enrdf_load_stackoverflow)
KR (1) KR102758660B1 (enrdf_load_stackoverflow)
CN (2) CN111565762A (enrdf_load_stackoverflow)
CA (1) CA3082056A1 (enrdf_load_stackoverflow)
IL (1) IL274518A (enrdf_load_stackoverflow)
WO (1) WO2019094657A1 (enrdf_load_stackoverflow)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3123873A1 (en) * 2018-12-21 2020-06-25 Actinium Pharmaceuticals, Inc. Combination radioimmunotherapy and immune checkpoint therapy in the treatment of cancer
MX2022006426A (es) * 2019-11-27 2022-06-22 Gi Innovation Inc Composicion farmaceutica para el tratamiento de cancer, que comprende inhibidor de punto de control inmunologico y proteina de fusion que incluye proteina il-2 y proteina cd80.
EP3842097A1 (en) * 2019-12-23 2021-06-30 Koninklijke Philips N.V. Planning radiation therapy using a personalized hematologic risk score
JP2023512214A (ja) 2020-01-28 2023-03-24 リフレクション メディカル， インコーポレイテッド 放射性核種および外部ビーム放射線療法の共同最適化
PE20221858A1 (es) * 2020-03-26 2022-11-30 Ramirez Fort Marigdalia Kaleth Tratamientos con radiacion ultravioleta
CN111840585B (zh) * 2020-07-20 2022-05-03 厦门大学 一种用于肿瘤免疫治疗的药物组合
US20220395702A1 (en) * 2021-06-10 2022-12-15 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for glioblastoma
KR20240142498A (ko) * 2022-01-28 2024-09-30 퓨전 파마슈티칼즈 인크. Ntsr1-표적화 방사성제약 및 체크포인트 억제제 조합 요법
WO2024258913A1 (en) * 2023-06-16 2024-12-19 Wisconsin Alumni Research Foundation Treatment of solid tumors with a regimen of targeted radionuclide therapy and genetically engineered immune cell therapies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
DK1729824T3 (da) * 2004-03-02 2009-11-02 Cellectar Inc Phospholipidanaloger til behandling af cancere
EP1833514A2 (en) * 2004-12-20 2007-09-19 Cellectar, Llc Phospholipid ether analogs for detecting and treating cancer
EP2440253B1 (en) * 2009-06-12 2020-05-13 Cellectar, Inc. Alkyl phospholipid compounds for treating cancer and imaging and detection of cancer stem cells
WO2016207732A1 (en) * 2015-06-25 2016-12-29 Advanced Accelerator Applications Method of treatment of neuroendocrine tumors that over-express somatostatatin receptors
EP3334465A1 (en) * 2015-08-12 2018-06-20 Bayer Pharma Aktiengesellschaft Pharmaceutical combination for the treatment of cancer
WO2017079535A1 (en) * 2015-11-06 2017-05-11 Wisconsin Alumni Research Foundation Long-lived gadolinium based tumor targeted imaging and therapy agents
US11633506B2 (en) * 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
AU2017300361B2 (en) * 2016-07-18 2024-08-01 Wisconsin Alumni Research Foundation Radiohalogenated agents for In Situ Immune Modulated Cancer Vaccination
US20180022768A1 (en) 2016-07-25 2018-01-25 Wisconsin Alumni Research Foundation Radioactive phospholipid metal chelates for cancer imaging and therapy
EP3487530B1 (en) * 2016-07-25 2024-03-20 Wisconsin Alumni Research Foundation Targeted radiotherapy chelates for in situ immune modulated cancer vaccination

Also Published As

Publication number Publication date
JP2021502368A (ja) 2021-01-28
CA3082056A1 (en) 2019-05-16
JP2023179556A (ja) 2023-12-19
AU2018366219A1 (en) 2020-06-11
IL274518A (en) 2020-06-30
KR102758660B1 (ko) 2025-01-22
CN111565762A (zh) 2020-08-21
WO2019094657A1 (en) 2019-05-16
KR20200088374A (ko) 2020-07-22
EP3706808A1 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
US20250195701A1 (en) Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies
KR102758660B1 (ko) 면역요법에 대한 항-종양 면역 반응을 유도하기 위해 표적화된 방사선요법(trt)을 이용하는 방법
US11730834B2 (en) Targeted radiotherapy chelates for in situ immune modulated cancer vaccination
US12109256B2 (en) Radiohalogenated agents for in situ immune modulated cancer vaccination
AU2018366219B2 (en) Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
CA3234495A1 (en) Combination therapy of radionuclide complex

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination